NAT2 and urinary bladder cancer: Furthermore, the individuals with NAT2 low acetylator phenotype had an almost 3.35-fold increased the risk of developing bladder cancer compared to individuals with NAT2 high acetylator phenotype (OR=3.35; 95% CI=0.86-13.07), (p=0.081).